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The leaves of Berkheya bergiana Soderberg (Asteraceae) were screened for phytochemical composition 
and antimicrobial potential. Phytochemical screening of the crude methanol extract showed the 
presence of various secondary metabolites. In vitro antimicrobial activities of the extracts obtained 
from six solvents were carried out against 28 bacterial strains using traditional methods. Chloroform 
extract exhibited the highest broad spectrum antibacterial activity against the tested bacteria and 
decreased in the order chloroform > ethyl acetate > butanol > hexane > aqueous extract at a 
concentration of 5.0 mg mL
-1
 for bacteria. The minimum inhibitory concentration (MIC) exhibited by 
EtOAc, CHCl3 and HEX extracts against the bacterial strains range between 0.07 and 2.5 mg mL
-1
, while 
that of BuOH and aqueous extracts ranged between 0.07 and 5.0 mg mL
-1
. The antibacterial activities of 
the plant were compared with standard (neomycin, ampicilin and tetracycline) antibiotics at the same 
concentration. The leaves extracts showed antibacterial potential, inhibiting the growth of some of the 
tested bacterial more than the standard drugs. The results obtained appeared to confirm the 
antibacterial potential of the plant investigated. 
 





South Africa has an abundance of medicinal plants, used 
in the traditional treatment of various diseases on an 
empirical basis (Hutchings and van Stedan, 1994; 
Neumann et al., 2004). The majority of the population of 
many developing countries uses herbal medicines either 
because people cannot afford western pharmaceuticals 
or because herbs are more acceptable (Cunningham, 
1991). Today, an estimated 80% of the black population 
of South Africa makes use of indigenous medicinal plants 
for the treatment of various ailments in man and animals 
(Kelmanson et al., 2000). This practice may be due to 
easy access to traditional medication, especially in rural 
areas, where the majority of people cannot afford pre-
scribed medicines. 
The problem of bacterial resistance to commonly used 
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necessitated the search for newer and alternative sour-
ces of drugs for the treatment of drug resistant infec-
tions. Medicinal plants have from generations been used 
for the treatment of ailments including infectious diseases. 
Several findings on the chemotherapeutics potential of 
some plants have shown that they can be good sources 
of antimicrobial compounds of value (Rios and Recio, 
2005).  
The genus Berkheya belongs to the Astereceae family. 
There are about 75 species of Berkheya with 71 species 
widespread in Southern Africa with about 30 species in 
the Natal region. B. bergiana Soderberg is an astera-
ceous perennial herb having leaves rough above with 
white cobwebby beneath, flower with yellow tips and 
spiny margins. The plant is extensively utilized in tradi-
tional medicinal practices in West, Central and South 
Africa. Decoction of leaves and roots are used for the 
treatment of coughs, gonorrhea, rheumatism and abdo-
minal disorders especially for pains after eating. It is also 
used  as  anti-emetics.   Unusual   sesquiterpenoids   and  




thiophene derivatives (isocomene, β-isocomene and 
modhepene) have been isolated from Berkheya species 
(Hutchings et al., 1996). 
This study is aimed at determining antibacterial  proper- 
ties of various extracts of B. bergiana leaves against 
some disease causing pathogens. The evaluation of anti-
bacterial activities of crude extracts is considered as an 
important step prior to isolation of bioactive compounds. 
The bacterial organisms used in this study are known to 








Fresh leaves of B. bergiana Soderberg were collected from their 
natural habitat within and around University of Zululand in March 
2007. Its identification was confirmed by Mrs. Anne Hutchings of 
the herbarium unit of the Botany Department, University of 
Zululand, KwaZulu-Natal, South Africa and voucher specimen 
deposited therein for reference purposes (Odeleye O.M. 2 (ZULU)).  
 
 
Preparation of extracts 
 
The leaves were air-dried at room temperature for 18 to 24 h and 
mechanically milled. Exactly 100 g of the powdered plant material 
was cold-extracted using 90% methanol for 2 days with occasional 
shaking. The extracts obtained from 3 cycles of extraction were 
combined after TLC analysis to ensure complete extraction. The 
mixture was then, filtered through Whatman filter paper no. 1 and 
the filtrate was concentrated to dryness using a rotary evaporator. 
This gave a yield of 19.39 g. (19.39%) 
In a subsequent method, the air-dried and powdered leaves of B. 
bergiana (370 g) were extracted sequentially with hexane, 
chloroform, ethyl acetate, butanol and water at room temperature 
for 2 days with occasional shaking. The extraction was repeated 3 
times. The extracts were filtered through Whatman filter paper no. 1 
and the filtrates were concentrated to dryness using a rotary 
evaporator. The various extracts were combined to obtain 4.99, 
5.53, 1.66, 4.71 and 2.78 g, respectively.  
 
 
Phytochemical screening of the plant extract 
 
A small portion of the dry methanolic extract was used for phyto-
chemical screening using standard procedures described by 
Sofowora (1982), Trease and Evans (1996) and Harborne (1998) 
for the determination of some of the secondary metabolites. 
 
 
Bacteria strains used in the study 
 
Bacteria strains used in this study consisted of  reference strains 
identified and obtained from University of Fort Hare namely 
Escherichia coli (ATCC 8739), E. coil (ATCC 25922), Pseudomonas 
aeruginosa (ATCC 19582), Staphylococcus aureus (ATCC 6538), 
Staphylococcus faecalis (ATCC 29212), Bacillus cereus (ATCC 
10702), Bacillus pumilus (ATCC 14884), P. aeruginosa (ATCC 
7700), Enterobacter cloacae (ATCC 13047), Klebsiella pneumonia 
(ATCC 10031), K. pneumonia (ATCC 4352), Proteus vulgaris 
(ATCC 6830), P. vulgaris (CSIR 0030), Serratia marscens (ATCC 
9986), Acinetobacter calcaoceuticus (Aci1), A. calcaoceuticus 





pneumonia, Bacillus subtilis, Shigella flexineri, Salmonella spp, 
Staphylococcus epidermidis, P. aeruginosa, P. vulgaris, 
Enterococcus faecalis, E. coil, S. aureus, Micrococcus kristinae and 
Micrococcus luteus.  
 
 
Assay for antibacterial activity 
 
Antibacterial activity of the extracts was carried out using the agar 
disc diffusion method described by Bauer et al. (1966). Bacteria 
were maintained on Mueller-Hinton nutrient agar at 4°C. Molten 
Mueller-Hinton agar was inoculated with a broth culture of the 
respective bacterial strains and poured over sterile 90 mm Petri 
dishes. The extract and fractions were dissolved in methanol to final 
concentration of 5.0 mg mL
-1
 and sterile Whatman no. 1 (6 mm) 
discs were impregnated with each sample to be tested at con-
centration of 5.0 mg mL
-1
. Each Petri dish with agar and bacteria 
contained one Whatman filter paper (no. 1) discs of 6.0 mm 
diameter with plant extracts. The plates were incubated at 37°C for 
24 h and the zones of inhibition were measured at the end of the 
incubation period. The standard antibiotics for reference drugs used 
were neomycin, ampicilin and tetracycline.  
 
 
Minimum inhibitory concentration 
 
The minimum inhibition concentration (MIC) of the plant extracts 
were determined using the 96 well microplate dilution method 
described by Eloff (1998). The final plate concentrations were 5.0, 
2.5, 1.25, 0.625, 0.313, 0.157, 0.078 and 0.039 mg mL-1 for the 
extract/fractions. Standard antibiotics (neomycin, ampicilin and 
tetracycline) were used as positive control. Bacteria were grown for 
18 h in nutrient broth and cultures of 108 colony forming unit (cfu) 
mL
-1
 were used and incubated for 24 h at 37°C. As an indicator of 
bacterial growth, 40 µl of 0.2 mg/ml p-iodonitrotetrazolium (INT) 
solution was added to each well and incubated at 37°C for 30 to 
120 min. The colorless tetrazolium salt was reduced to a red 
colored product by biological activity of the organisms, thereby 
making the inhibition of bacterial growth visible as clear well. MIC 
values were recorded as the lowest concentration in which there 
was no bacterial growth. Each treatment was replicated thrice. 
 
 
Analysis of data 
 
All values are expressed as means ± standard error. The data 
collected was analyzed using one-way analysis of variance 
(ANOVA) and the effect of the differences among group means 
were considered significant when P value was < 0.05 
 
 
RESULTS AND DISCUSSION 
 
The result of the phytochemical screening of methanolic 
extract is listed in Table 1. The analysis showed the 
presence of secondary metabolites including flavonoids, 
saponins, tannins, trace of alkaloids, phenolic com-
pounds and glycosides but no traces of anthraquinones 
in the methanolic extract. These secondary metabolites 
have earlier been reported to exhibit antimicrobial activity 
(Hostettman and Nakanishi, 1979). Therefore, these 
compounds may be responsible for the antibacterial 
activity of the leave extracts of B. bergiana. Tannins for 
example have been found to form irreversible complexes 
with proline-rich proteins (Hagerman and Butler, 1981).  




Table 1. Phytochemical screening of B. bergiana methanol extract. 
 
Plant metabolites B. bergiana 
Alkaloids  
(a) Preliminary screen 
Draggendorff’s reagent 
Mayer’s reagent 






 Anthraquinones  
(a) Free                            
(b) Combined  












Cardiac glycosides (Keller-Kiliani test for deoxy sugars) +++ 
  
Flavonoids 
Lead acetate test 
Sodium hydroxide test 
Ferric chloride test  
HCl + Mg turning 







Flavonol (Shinoda reduction test) ++ 
  
Terpenoids (Liebermann-Buchard test) +++ 
  
Steroids and sterols (Salkowski test) + 
  
Saponins  
Frothing test      







Ferric chloride test 










Herbs that contain tannins as their main constituents are 
astringent in nature and are used for treating intestinal 
disorders such as diarrhea and dysentery (Dharmananda, 
2003) which is one of the traditional uses of B. bergiana 
plant. Quinlan et al.  (2000)  and  Neumann  et  al. (2004) 
showed that, steroids and steroidal extracts exhibiting 
antibacterial and antiviral activities, respectively. Thus, 
the  presence  of   these  compounds  in  B. bergiana  corro- 
borates the antibacterial activities observed.  
In South Africa, B. bergiana plant has been used to 
treat cough and abdominal disorder infections (Hutchings 
et al., 1996). The antibacterial activities against some of 
the tested bacterial strains at a concentration of 5.0 mg 
mL
-1
 of the extracts of B. bergiana are presented in Table 
2. The  hexane,  chloroform,  ethyl  acetate,  butanol  and 
aqueous extracts of the leaf extracts displayed broad




Table 2. The antibacterial activities of crude extract and fractions of B. bergiana. 
 
Bacterial and extracts 
Zone of inhibition (mm) 
Crude Hexane CHCl3 EtOAc BuOH Aqueous Neomycin Ampicilin Tetracycline 
E. coil (ATCC 8739) 9.0 ± 1.41 12.5 ± 2.0 10.5 ± 0.5 9.0 ± 0.75 11.0 ± 2.5 9.5 ± 0.75 17.5 ± 1.5 17.5 ± 2.0 22.0 ± 2.5 
E. coil (ATCC 25922) 9.5 ± 0.00 7.5 ± 1.0 11.5 ± 2.0 10.0 ± 0.0 12.5 ± 0.0 10.5 ± 0.50 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
P. aeruginosa(ATCC 19582) 12.0 ± 0.00 13.0 ± 2.0 12.0 ± 0.7 15.0 ± 2.0 12.5 ± 0.50 11.5 ± 0.75 18.0 ± 0.75 10.0 ± 0.25 17.0 ± 0.25 
S. aureus (ATCC 6538) 13.0 ± 0.00 13.5 ± 2.5 10.5 ± 1.0 15.5 ± 2.5 9.0 ± 0.25 12.0 ± 0.50 25.5 ± 0.0.5 39.0 ± 0.25 28.5 ± 0.75 
S. faecalis (ATCC 29212) 9.0 ± 1.10 16.0 ± 2.0 0.0 ± 0.0 10.5 ± 1.0 0.0 ± 0.0 8.0 ± 0.75 0.0 ± 0.0 0.0 ± 0.0 15.0 ± 1.0 
B. cereus (ATCC 10702) 10.5 ± 0.75 8.0 ± 0.75 13.5 ± 0.5 8.0 ± 0.75 13.0 ± 1.0 12.0 ± 0.75 21.0 ± 1.0 17.0 ± 0.25 29.0 ± 1.25 
B. pumilus (ATCC 14884) 10.0 ± 0.00 7.0 ± 0.75 11.0 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 12.0 ± 1.0 24.5 ± 0.25 36.0 ± 0.75 20.5 ± 0.50 
P. aeruginosa (ATCC 7700) 9.0 ± 1.41 15.6 ± 1.0 18.5 ± 2.5 14.0 ± 0.5 15.0 ± 0.75 13.5 ± 0.25 18.5 ± 0.25 32.5 ± 0.75 19.0 ± 0.75 
E. cloacae (ATCC 13047) 10.0 ± 0.25 10.0 ± 1.0 15.5 ± 2.0 13.0 ± 0.25 10.0 ± 2.0 8.5 ± 0.00 18.5 ± 0.25 0.0 ± 0.0 23.5 ± 1.0 
K. pneumonia(ATCC 10031) 11.0 ± 0.75 16.0 ± 2.0 16.0 ± 0.5 13.0 ± 0.50 14.5 ± 0.0 13.0 ± 2.5 23.5 ± 0.5 15.0 ± 0.25 29.5 ± 2.0 
K. pneumonia (ATCC 4352) 11.5 ± 0.75 11.0 ± 1.0 13.0 ± 2.0 10.0 ± 1.0 11.0 ± 0.0 10.5 ± 0.75 19.0 ± 1.0 11.0 ± 0.75 25.0 ± 2.0 
P. vulgaris (ATCC 6830) 10.0 ± 3.53 10.0 ± 0.5 10.0 ± 1.0 11.0 ± 0.75 10.0 ± 0.5 9.0 ± 0.0 21.5 ± 1.55 24.0 ± 0.5 20.0 ± 0.25 
P. vulgaris (CSIR 0030) 0.0 ± 0.0 12.5 ± 2.0 0.0 ± 0.0 8.0 ± 1.25 8.0 ± 0.75 12.0 ± 0.0 16.5 ± 0.5 11.5 ± 0.50 14.0 ± 0.75 
S. marscens (ATCC 9986) 0.0 ± 0.0 9.5 ± 1.0 0.0 ± 0.0 9.0 ± 0.5 9.0 ± 0.25 11.0 ± 1.0 16.5 ± 0.0 0.0 ± 0.0 19.5 ± 0.25 
A. calcaoceuticus Aci1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
A. calcaoceuticus Aci2 0.0 ± 0.0 9.5 ± 2.0 0.0 ± 0.0 0.0 ± 0.0 8.0 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
K.  pneumonia 8.0 ± 1.00 11.0 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 7.5 ± 0.5 11.5 ± 2.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
B. subtilis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 25.5 ± 1.0 43.0 ± 2.0 40.0 ± 2.5 
S. flexineri 11.5 ± 0.25 0.0 ± 0.0 8.0 ± 0.75 15.5 ± 2.5 12.0 ± 2.0 0.0 ± 0.0 12.5 ± 0.5 25.5 ± 0.75 30.0 ± 0.25 
Salmonella spp 9.0 ± 0.75 10.5 ± 1.0 10.0 ± 0.5 10.0 ± 1.0 9.5 ± 0.75 0.0 ± 0.0 15.0 ± 0.0 26.5 ± 0.25 30.5 ± 0.25 
S. epididirmis 9.0 ± 0.75 9.0 ± 0.75 8.5 ± 1.5 9.0 ± 0.50 10.0 ± 1.0 8.5 ± 0.25 30.0 ± 1.5 29.5 ± 0.75 17.5 ± 0.5 
P. aeruginosa 12.0 ± 0.25 8.0 ± 0.25 9.0 ± 2.5 9.5 ± 0.75 0.0 ± 0.0 0.0 ± 0.0 26.5 ± 1.0 30.0 ± 1.5 32.5 ± 2.0 
P. vulgaris 10.5 ± 0.50 8.5 ± 0.75 11.0 ± 0.0 9.5 ± 0.75 11.0 ± 0.75 0.0 ± 0.0 17.5 ± 0.25 12.5 ± 0.5 15.0 ± 0.5 
E. faecalis 0.0 ± 0.0 0.0 ± 0.0 13.0 ± 1.0 10.0 ± 0.75 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 35.5 ± 1.5 13.5 ± 0.25 
E. coil 8.0 ± 0.25 15.5 ± 0.5 11.0 ± 2.5 9.0 ± 0.5 17.0 ± 2.5 0.0 ± 0.0 19.5 ± 0.75 22.5 ± 0.5 27.5 ± 0.5 
S. aureus 9.0 ± 0.50 10.0 ± 0.5 11.5 ± 0.5 8.5 ± 0.5 8.0 ± 0.50 0.0 ± 0.0 21.0 ± 1.75 41.5 ± 3.0 34.5 ± 2.5 
M. kristinae 8.5 ± 1.00 7.0 ± 0.25 8.5 ± 0.75 11.5 ± 2.0 9.5 ± 0.25 7.0 ± 0.25 16.5 ± 0.0 15.0 ± 0.25 32.5 ±1.0 
M. luteus 9.5 ± 1.50 9.5 ± 2.0 11.0 ± 0.0 12.5 ± 0.25 12.5 ± 1.0 10.0 ± 1.0 26.0 ± 0.0 16.0 ± 0.0 24.5 ± 0.5 
 
Dose, 5 mg mL
-1
; disc diameter, 6 mm; *, significantly different from the control (P < 0.05) by using analysis of variance (ANOVA). The data given are mean (n = 3) ± standard error. 




Table 3. Minimum inhibitory concentration (MICs) of the crude extract and fractions of B. bergiana leaves. 
 
Bacterial and extracts 
MIC (mg/ml) 
Crude Hexane CHCl3 EtOAc BuOH Aqueous Neomycin Ampicilin Tetracycline 
E. coil (ATCC 8739) 0.312 5.000 2.500 1.250 0.039 0.039 0.039 0.039 0.039 
E. coil (ATCC 25922) 1.250 5.000 1.250 - 1.250 0.625 - - - 
P. aeruginosa(ATCC 19582) 1.250 5.000 0.156 0.156 0.312 0.156 0.039 0.039 0.156 
S. aureus (ATCC 6538) 0.625 5.000 0.625 0.312 0.312 - 0.039 2.500 0.039 
S. faecalis (ATCC 29212) 2.500 5.000 - 0.625 - 1.250 - - 0.078 
B. cereus (ATCC 10702) 2.500 - 1.250 0.625 1.250 5.000 0.039 5.000 0.039 
B. pumilus (ATCC 14884) 2.500 - 2.500 - - - 0.039 5.000 0.156 
P. aeruginosa (ATCC 7700) 0.625 2.500 0.312 1.250 0.625 2.500 0.039 0.039 0.156 
E. cloacae (ATCC 13047) 0.312 5.000 0.0780 0.078 0.078 0.312 0.039 - 0.078 
K. pneumonia(ATCC 10031) 0.625 2.500 0.625 1.250 0.312 - 0.039 - 0.156 
K. pneumonia (ATCC 4352) 2.500 5.000 1.250 0.625 0.625 - 0.039 1.250 0.039 
P. vulgaris (ATCC 6830) 1.250 1.250 1.250 0.312 0.625 - 0.039 - 0.039 
P. vulgaris (CSIR 0030) ND ND ND ND ND ND ND ND ND 
S. marscens (ATCC 9986) ND ND ND ND ND ND ND ND ND 
A. calcaoceuticus Aci1 (LIO) ND ND ND ND ND ND ND ND ND 
A. calcaoceuticus Aci2 (LIO) ND ND ND ND ND ND ND ND ND 
K.  pneumonia (LIO) ND ND ND ND ND ND ND ND ND 
B. subtilis (LIO) ND ND ND ND ND ND ND ND ND 
S. flexineri (LIO) 0.625 - 0.625 0.625 0.625 - 0.039 1.25 0.039 
Salmonella spp (LIO) 0.625 5.000 0.625 0.625 0.156 - 0.039 0.156 0.039 
S. epididirmis (LIO) 0.312 5.000 0.156 0.156 1.250 0.312 0.039 0.625 0.039 
P. aeruginosa (LIO) 0.312 5.000 0.312 0.312 - - 0.039 2.500 0.039 
P. vulgaris (LIO) 0.078 2.500 0.078 0.039 0.039 - 0.039 0.312 0.039 
E. faecalis (LIO) - 2.500 0.625 0.625 - - - 0.039 0.039 
E. coil (LIO) 0.078 2.500 0.625 0.625 0.039 - 0.039 0.625 0.039 
S. aureus (LIO) 0.078 - 2.500 2.500 2.500 - 0.039 0.039 0.039 
M. kristinae (LIO) ND ND ND ND ND ND ND ND ND 
M. luteus (LIO) ND ND ND ND ND ND ND ND ND 
 
ATCC, American type culture collection; CSIR, Council for Scientific and Industrial Research; LIO, locally isolated organism; CHCl3, chloroform; 




inhibitory effect against the tested bacteria at various 
degrees. However, these various extracts may contain 
different chemical constituents in different solvents due to 
their polarity and so, these components of each extract 
were responsible for the antibacterial activities of different 
extracts by diffusion of the components of each extract 
using water-based agar. This support Freiburghans et al. 
(1996) that, different solvent system extracts of some 
plant may exhibit diffe-rent pharmacological properties. 
The most sensitive bacteria to the six extracts were P. 
aeruginosa, S. aureus, B. cereus, K. pneumonia, E. coli, 
P. vulgaris and M. luteus. The chloroform and ethyl 
acetate extracts were the most active extracts. However, 
chloroform was more active with zones of inhibition 
ranging between 8.0 and 18.5 mm while the hexane and 
aqueous fractions showed low activity with the aqueous 
extract showing least activities with zones of inhibition 
ranging between 7.5 and 13.0 mm. Though water had 
been reported by traditional healers and herbalists to be 
the most commonly used solvent to extract biologically 
active compounds due to its easy availability but semi-
organic solvents are more active. In comparison with 
standard commercial drugs, the antibacterial property of 
B. bergiana leaves (inhibition zones of 9.7 to 16.0 mm 
diameter) was as effective as the commercial antibiotics 
tetracycline, neomycin and ampicillin (inhibition zones of 
11.0 to 43.0 mm) in some bacteria. The MIC of the 
extracts of B. bergiana leaves range from 5.0 to 0.07812 
mg/ml (Table 3). The most active extract was chloroform 
with MIC ranges from 2.5 to 0.07812 mg/ml. The ability of 
the extracts from B. bergiana to inhibit the growth of 
some of the tested bacteria strains like E. coli, S. aureus, 
S. flexineri, P. vulgaris and P. aeruginosa is an indication 
of the potential of the plant as a broad spectrum 
antibacterial agent. B. bergiana has been used 
traditionally for the treatment of various respiratory 
diseases by the people of Kwazulu-Natal for a long time. 
B. cereus and K. pneumonia are  respiratory  bpathogens  




commonly associated with cold and flu (Viljoen et al., 
2004). The inhibitory property of the extracts from B. 
bergiana against pathogens might have justified the use 
of this plant for the treatment of cough and influenza 
fever by people of Kwazulu-Natal. The results also  
indicated that, the extracts exhibited antibacterial activity 
against E. coli and S. aureus, the causative micro-
organisms of abdominal disorder like diarrhea. As these 
bacteria are implicated in opportunistic infections and the 
extract showed pronounced activity against some of 
them, the extract may be useful in management of such 
opportunistic infections 
B. bergiana is a plant that has shown tremendous 
potential as a source of novel chemotherapeutic agents. 
It is therefore, one of the prime medicinal plants of Africa 
that can provide relief to the millions of the poor people of 
the continent if its potentials are adequately explored. 
This plant B. bergiana displayed a better antibacterial 
activity against indicator organisms. Hence, extracts have 
potential of being used as source of biopharmaceutical 
substances with antibacterial property. Further work 
aimed at isolation and identification of specific anti-
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